SPARSENTAN VS IRBESARTAN IN PATIENTS WITH IMMUNOGLOBULIN A NEPHROPATHY (IgAN): SUBGROUP ANALYSES OF 2-YEAR RESULTS FROM THE PIVOTAL PHASE 3 PROTECT TRIAL

15 Apr 2024 3:35 p.m. 3:45 p.m.
JonathanBarratt Free Communication United KingdomUniversity of Leicester, Leicester, UK